The effects of increased serotonergic activity on human sensory gating and its neural generators

被引:30
作者
Jensen, Kristian S. [1 ]
Oranje, Bob [1 ]
Wienberg, Malene [1 ]
Glenthoj, Birte Y. [1 ]
机构
[1] Univ Copenhagen, Univ Psychiatr Ctr Glostrup, Fac Hlth Sci, Ctr Neuropsychiatr Schizophrenia Res, Glostrup 2600, Denmark
关键词
P50; suppression; source localization; sensory gating; escitalopram; serotonin;
D O I
10.1007/s00213-007-1001-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale Schizophrenia is a disabling illness with deficits in core mental functions such as sensory gating. The P50 amplitude is an (usually auditory) evoked brain potential that, in a so-called double-click paradigm, can be used to quantify sensory gating. Reports on serotonergic modulation of P50 suppression are sparse. Objective The objective of this study was to study the effects of increased serotonergic activity on parameters of P50 suppression in healthy volunteers. Materials and methods In a double-blind placebo-controlled crossover design, 21 healthy male volunteers received either placebo or a dose of 10 mg of escitalopram (selective serotonin reuptake inhibitor), after which they were tested in a P50 suppression paradigm. Furthermore, an attempt was made to identify the neural generators of the P50 evoked potential. Results Escitalopram did not affect P50 suppression but was found to increase P50 amplitude to the first (or conditioning) stimulus. Two bilateral sources located in the temporal cortex, two bilaterally located near the eyes, and one in a fronto-central location were identified, the latter correlating positively with the P50 amplitude. Conclusions In the current study, escitalopram did not affect P50 suppression in healthy male volunteers, which indicates that sensory gating is not affected by a nonspecific increase in serotonergic activity. Furthermore, a generator with a fronto-central location in the brain (possibly the anterior cingulate) was found to be the primary source of the P50 evoked potential.
引用
收藏
页码:631 / 641
页数:11
相关论文
共 57 条
[1]  
ADLER LE, 1982, BIOL PSYCHIAT, V17, P639
[2]   Improved P50 auditory gating with ondansetron in medicated schizophrenia patients [J].
Adler, LE ;
Cawthra, EM ;
Donovan, KA ;
Harris, JG ;
Nagamoto, HT ;
Olincy, A ;
Waldo, MC .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (02) :386-U5
[3]   Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients [J].
Adler, LE ;
Olincy, A ;
Cawthra, EM ;
McRae, KA ;
Harris, JG ;
Nagamoto, HT ;
Waldo, MC ;
Hall, MH ;
Bowles, A ;
Woodward, L ;
Randal, R ;
Freedman, R .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10) :1822-1828
[4]   YOHIMBINE IMPAIRS P50 AUDITORY SENSORY GATING IN NORMAL SUBJECTS [J].
ADLER, LE ;
HOFFER, L ;
NAGAMOTO, HT ;
WALDO, MC ;
KISLEY, MA ;
GIFFITH, JM .
NEUROPSYCHOPHARMACOLOGY, 1994, 10 (04) :249-257
[5]   A MULTIPLE SOURCE APPROACH TO THE CORRECTION OF EYE ARTIFACTS [J].
BERG, P ;
SCHERG, M .
ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1994, 90 (03) :229-241
[6]   Acute citalopram administration produces correlated increases in plasma and salivary cortisol [J].
Bhagwagar, Z ;
Hafizi, S ;
Cowen, PJ .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :118-120
[7]   REPLICATION AND EXTENSION OF P50 FINDINGS IN SCHIZOPHRENIA [J].
BOUTROS, NN ;
ZOURIDAKIS, G ;
OVERALL, J .
CLINICAL ELECTROENCEPHALOGRAPHY, 1991, 22 (01) :40-45
[8]  
BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181
[9]   Meta-analysis of the P300 and P50 waveforms in schizophrenia [J].
Bramon, E ;
Rabe-Hesketh, S ;
Sham, P ;
Murray, RM ;
Frangou, S .
SCHIZOPHRENIA RESEARCH, 2004, 70 (2-3) :315-329
[10]   P50 suppression in individuals at risk for schizophrenia: The convergence of clinical, familial, and vulnerability marker risk assessment [J].
Cadenhead, KS ;
Light, GA ;
Shafer, KM ;
Braff, DL .
BIOLOGICAL PSYCHIATRY, 2005, 57 (12) :1504-1509